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SHIP2, OCRL, and INPP5B belong to inositol poly-
phosphate 5-phophatase subfamilies involved in
insulin regulation and Lowes syndrome. The struc-
tural basis for membrane recognition, substrate
specificity, and regulation of inositol polyphos-
phate 5-phophatases is still poorly understood. We
determined the crystal structures of human SHIP2,
OCRL, and INPP5B, the latter in complex with
phosphoinositide substrate analogs, which revealed
a membrane interaction patch likely to assist in
sequestering substrates from the lipid bilayer. Resi-
dues recognizing the 1-phosphate of the substrates
are highly conserved among human family members,
suggesting similar substrate binding modes. How-
ever, 3- and 4-phosphate recognition varies and de-
termines individual substrate specificity profiles. The
high conservation of the environment of the scissile
5-phosphate suggests a common reaction geometry
for all members of the human 5-phosphatase family.
INTRODUCTION
Membrane-bound phosphoinositides (PtdInsP) and the corre-
sponding soluble inositol phosphates (InsP) regulate a multitude
of cellular processes including cell proliferation, synaptic vesicle
recycling, receptor signaling, and actin polymerization (Di Paolo
and De Camilli, 2006; Michell, 2008). They consist of a glycerol-
phospholipid linked through a phosphodiester bond to the
hydroxyl in position 1 of a myo-inositol molecule. Hydroxyls in
positions 3, 4, and 5 on themyo-inositol ring can be phosphory-
lated by kinases, thus generating the seven possible isoforms
that have so far been identified in higher eukaryotes. These
phosphorylation events can be reverted by the antagonist action
of specific phosphatases. The consequence is that each phos-
phorylated isoform mediates specific signaling pathways while744 Structure 22, 744–755, May 6, 2014 ª2014 Elsevier Ltd All rightsalso being an intermediate in the production of other phosphor-
ylated isoforms (reviewed in Hakim et al., 2012 and Maffucci,
2012). For example, PtdIns(4,5)-bisphosphate is involved in
vesicle trafficking (Martin, 2001), ion-channel regulation (Gamper
and Shapiro, 2007), endocytosis (Poccia and Larijani, 2009),
exocytosis (Eberhard et al., 1990), actin polymerization (Hartwig
et al., 1995; Tolias et al., 2000), and is the precursor of
PtdIns(3,4,5)-triphosphate through the action of type I phosphoi-
nositide 3-kinase (PI3K; Vanhaesebroeck et al., 1997).
The variety of processes regulated by phosphoinositides
is illustrated by the large spectrum of diseases in which they
have been implicated, such as cardiovascular diseases, dia-
betes, neurological diseases, ciliopathies, and cancers (Conduit
et al., 2012; Hakim et al., 2012). Phosphatidylinositol 3-kinases
(PI3Ks) are frequently mutated in human cancers and the PIK3
opposing phosphatase PTEN is the second most commonly
mutated tumor suppressor after p53 (Ligresti et al., 2009; Liu
et al., 2009; Samuels et al., 2004; Yin and Shen, 2008). Myotubu-
larins, which catalyze the hydrolysis of the 3-phosphate on phos-
phoinositides, are mutated in X-linked centronuclear myopathy
and demyelinating Charcot-Marie Tooth neuropathies and are
also connected to cancers, epilepsy, and obesity (Amoasii
et al., 2012; Azzedine et al., 2003; Bolino et al., 2000; Laporte
et al., 1996; Senderek et al., 2003). Consequently, several pro-
teins involved in phosphoinosite-based signaling constitute
important targets for therapeutic intervention (Blunt and Ward,
2012; McCrea and De Camilli, 2009; Moses et al., 2009; Suwa
et al., 2010a; Waugh, 2012).
The inositol polyphosphate 5-phosphatases (5-phosphatases)
regulate phosphoinositide signaling by hydrolyzing the 5-phos-
phate position of the inositol ring of both soluble inositol phos-
phates and membrane-bound phosphoinositides (primarily
PtdIns(3,4,5)P3, PtdIns(4,5)P2, and PtdIns(3,5)P2), with different
substrate preferences (Astle et al., 2007). This family comprises
ten members in mammals that share the catalytic 5-phospha-
tase domain. Five-phosphatases play important roles in human
health (Ooms et al., 2009). The 5-phosphatase OCRL is respon-
sible for the oculocerebrorenal syndrome of Lowe, which leads
to neurological and renal defects (Attree et al., 1992). Mutations
in OCRL also cause Dent disease, which, like Lowes syndrome,reserved
Figure 1. Structure of Complex between
INPP5B-cd and diC8PtdIns(3,4)P2: Overall
View and Comparison with SHIP2, OCRL,
and SPsynaptojanin
(A) Ribbon diagram of INPP5B-cd bound
to diC8PtdIns(3,4)P2. Mg2+ ion is shown as an
orange sphere. Motifs LC1R, LC2R, and P4IM
are colored respectively orange, green and
purple.
(B) Superimpositionof INPP5B-cd/diC8PtdIns(3,4)
P2 complex (blue), SHIP2-cd (red), and OCRL-cd
(green) Ca traces.
(C) Superimposition of INPP5B-cd/diC8PtdIns(3,4)P2 complex (blue) and SPsynaptojanin-cd bound to inositol (1,4)-bisphosphate. Carbon atoms of
diC8PtdIns(3,4)P2 complex and of inositol (1,4)-bisphosphate are yellow and green, respectively. Mg2+ ion in INPP5B-cd is shown as an orange sphere, Ca2+ ion
in SPsynaptojanin-cd as a green sphere.
See also Figure S2 for the location of a putative Ca2+ ion observed in the structure of apo-INPP5B-cd.
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Substrate Processing by the PtdIns 5-phosphatasesis an X-linked disorder characterized by kidney failure (Hoopes
et al., 2005). To date, about 200 different mutations have been
identified in OCRL, most of the missense mutations being
located in the 5-phosphatase domain of the protein (Pirruccello
and De Camilli, 2012; Zhang et al., 2013). OCRL shares 44%
sequence identity with INPP5B and the function of INPP5B
and OCRL is likely overlapping (Hellsten et al., 2001; Ja¨nne
et al., 1998). The 5-phosphatase SHIP2 negatively regulates in-
sulin-mediated signaling (Dyson et al., 2005), and mice deficient
in SHIP2 are resistant to diet-induced obesity (Sleeman et al.,
2005). SHIP2 is therefore potentially an interesting drug target
for obesity and type 2 diabetes. Mutations in the 5-phosphatase
domain of INPP5E have also been identified in the Joubert syn-
drome type of ciliopathy (Bielas et al., 2009).
Despite many links to disease, the understanding of important
aspects of phosphoinositide signaling is still limited. At the pro-
tein level, the molecular basis for how substrate recognition
and membrane interactions control specificity and activity re-
mains rudimentary for most of the enzyme families of these path-
ways. The only structure of a 5-phosphatase catalytic domain
previously reported is that of Schizosaccharomyces pombe
synaptojanin (SPsynaptojanin), which revealed a fold similar to
that of Mg2+-dependent endonucleases (Tsujishita et al., 2001).
The structure was determined in complex with a soluble
inositol(1,4)P2 product and thus did not provide any information
on how the 5-phosphatases are able to accommodate the
lipid moieties of their substrates. In addition, the orientation of
inositol(1,4)P2 in the active site of SPsynaptojanin does not facil-
itate proper modeling of an intact substrate due to steric clashes
with the region expected to accommodate the 5-phosphate.
Thus, whereas the current model gives a rough estimation on
the region that mediates the natural ligand, detailed information
concerning substrate position and orientation, interactions be-
tween the protein and the fatty acid part of the phosphoinositi-
des, and the catalytic mechanism in the 5-phosphatase family
are not available. Understanding these aspects is essential to
provide a link between the missense mutations that have been
identified in the 5-phosphatase catalytic domains and the dis-
eases they are responsible for. This is exemplified by the pheno-
typical differences that exist between Lowe syndrome and the
milder Dent disease that can be both caused by mutations tar-
geting the catalytic domain of OCRL. Currently, the incomplete
model of protein/ligand interactions in the 5-phosphatase family
does not allow discrimination between effects caused by aStructure 22destabilizing mutation and effects due to alterations either in
the catalytic machinery or in the ligand-binding site.
To answer these points as well as to understand the molecular
basis for membrane interaction in the human 5-phosphatase
family, we have determined structures of the catalytic domains
of the human 5-phosphatases SHIP2, OCRL, and INPP5B, the
latter in complex with two PtdInsP products. These studies
give a detailed view of the catalytic machinery and structural fea-
tures involved in substrate recognition for key members of the
human 5-phosphatase family and revealed striking differences
in the substrate binding-mode compared to what has previously
been suggested from the SPsynaptojanin structure.
RESULTS
Overall Structures of OCRL and INPP5B Catalytic
Domains
Useful crystals of the INPP5B and OCRL catalytic domains
(INPP5B-cd and OCRL-cd) were obtained after extensive
screening of constructs expressing soluble and stable protein
using the strategydescribedbyGra¨slundet al. (2008). Thesecon-
structs lack theirC-terminal Rho-GAPdomains and theirN-termi-
nal PH domains, the latter being responsible for the targeting of
OCRL to endocytic clathrin-coated pits (Erdmann et al., 2007)
mediated through interaction with both clathrin and endocytic
clathrin adaptor AP-2 (Ungewickell et al., 2004), whereas its func-
tion remains unknown in INPP5B (Mao et al., 2009). The purified
catalytic domains were active toward phosphoinositide sub-
strates in vitro (see below). First a 2.65 A˚ resolution structure of
INPP5B-cd was determined in the presence of high Mg2+ con-
centration (200 mM Mg2+), revealing an overall fold similar to
the SPsynaptojanin catalytic domain (Protein Data Bank [PDB]
number 1I9Y, root-mean-square deviation [rmsd] 1.2 A˚ for 273
superimposed residues, sequence identity of 34%; for sequence
alignment, see Figure S1 available online). The fold is composed
of a b sandwich, which is lined by several a helices. Subse-
quently, structures of INPP5B in complex with product analogs
were determined (Figure 1A). A tentative catalytic Mg2+ ion was
found in the active site of all INPP5Bstructures. A residual density
that could not be attributed to either protein or water molecules
was observed in apo-INPP5B-cd maps at Asp414, ca 15 A˚
from the catalyticMg2+ ion. Its size andcoordination environment
looked similar to what can be expected of a Ca2+ ion (Figure S2;
this is the identity in the apo-INPP5B-cd model deposited to the, 744–755, May 6, 2014 ª2014 Elsevier Ltd All rights reserved 745
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Substrate Processing by the PtdIns 5-phosphatasesPDB). Despite extensive efforts, but hampered by the relative
instability of the produced protein, we have not been able to
conclusively characterize either the nature of this ion or its poten-
tial role in the function of INPP5B.
The structure of OCRL-cd was determined at 3.13 A˚ resolution
using molecular replacement with INPP5B-cd as a searchmodel
(Figure 1B). The rmsd between OCRL-cd and the INPP5B-cd
structures is in the range of 0.7–0.8 A˚. The construct of OCRL
carries longer C-and N-terminal extensions, where ca 30 C-ter-
minal residues are ordered forming a small two-helix coiled-
coiled domain. An Mg2+ and a phosphate ion are found in the
active site of OCRL. The structure of SHIP2 will be discussed
below. Data collection and refinement statistics are shown in
Table 1.
To verify the integrity of the constructs used for structural
studies, we also assayed the OCRL-cd and the INPP5B-cd con-
structs, as well as several other human 5-phosphatases for
activity using the malachite green assay to monitor phosphate
release from diC8PtdInsP substrates. diC8PtdlnsPs are soluble
analogs of phosphoinositides, having identical head groups but
shorter eight-carbon aliphatic chains. All proteins were active
against two different substrate analogs, diC8PtdIns(3,4,5)P3
and diC8PtdIns(4,5)P3, albeit with different activity profiles (Fig-
ure 2B). We noted that, with the exception of SHIP2, the molecu-
lar activity of the 5-phosphatases we assayed were in the
same range. Possibly our assay conditions were not optimal for
SHIP2, or its low activity (relatively to the other 5-phosphatases
present in our study) could be either due to the strong require-
ment of its N- and C-terminal domains to reach optimal activity
or might be a specificity intrinsic to this enzyme that by many
points differ from the consensus 5-phosphatases as discussed
later in the article.
Recognition of Phosphoinositide Substrates in INPP5B
Extensive diffraction screening of crystals obtained in co-crystal-
lization experiments of INPP5B-cd with diC8PtdIns(3,4,5)P3
yielded two crystals giving data of sufficient quality for structural
analysis. The refined structures contained two different hydroly-
sis products, diC8PtdIns(4)P and diC8PtdIns(3,4)P2. We attri-
bute the presence of two different hydrolysis products to
different storage times of the crystals in their growth containers.
The binding modes of the two products are virtually identical in
the lipophilic region of the substrate as well as for the 1-P unit,
whereas the position of the inositol ring and 4-phosphate groups
overlap albeit having slightly different orientations in the two
structures (Figures 3A and 3B).
The substrates bind to one terminus of the b sandwich where
the substrate interactions are made by several loops and short
helices connecting the b strands (Figure 1A). The aliphatic region
of the diC8PtdInsP products is primarily interacting with a patch
composed of two hydrophobic loops: one including Phe311,
Phe312, and Phe313, termed lipid chain 1 recognition motif
(LC1R-motif); and a second loop being composed of Ile373,
Met374, and Met377, termed lipid chain 2 recognition motif
(LC2R-motif; Figure 3C).
The 1-P group of the substrate constitutes, together with the
inositol ring, the conserved polar moiety of all phosphoinositide
substrates and is expected to be a key unit for substrate recog-
nition. In the INPP5B-cd product complexes, the 1-P moiety is746 Structure 22, 744–755, May 6, 2014 ª2014 Elsevier Ltd All rightsrecognized by direct hydrogen bonds with the side chains of
Asn379 and Lys380 (Figure 3C). Several water molecules, stabi-
lized by protein coordination, also make hydrogen bonds with
1-P (see LIGPLOT diagram in Figure 3D). The only direct recog-
nition of the inositol ring in the product complexes is by the
Ala403 side chain where the b carbon is lining the ring (Figures
3A and 3D), whereas the 6-OH group in the product complexes
is coordinated by a protein-bound water molecule (Figure 3D). In
the product structures of INPP5B-cd, the 4-P group is pinned
down in the active site by extensive interactions with the protein
through a conserved structural pattern we term the P4-interact-
ing-motif (P4IM), composed of Tyr502, Lys503, Arg518, and Lys
516, as well as a protein coordinated water molecule. In the
PtdIns(3,4)P2 complex of INPP5B, the 3-P position is relatively
exposed into the solvent but makes a hydrogen bond to
His404 (Figure 3A). The fact that INPP5B exhibits extensive inter-
actions with the 4-P group explains its preference for PtdIns(4,5)
P2 and PtdIns(3,4,5)P3, and inability to hydrolyse PtdIns(5)P and
PtdIns(3,5)P2 (Schmid et al., 2004).
Superposition with the structure of SPsynaptojanin com-
plexed to Ins(1,4)P2 reveals that the metal ions superimpose
closely and the products are located in the same cleft, but that
the orientation of the inositol moieties of the ligands shows sig-
nificant differences (Figures 1C and 5I). Whereas the 4-Ps of
both products are separated by only 1.8 A˚ and thus exhibit
a similar binding mode mediated by conserved residues, the
inositol moieties are rotated relative to each other by approxi-
mately 100, so that their 1-Ps are projected to be 10.3 A˚ apart
(Figure 5I).
Interactions with Scissile Phosphate and Catalytic
Mechanism
To gain further insights into substrate recognition and the cata-
lytic mechanism, we initially attempted to trap a nonhydrolyzed
substrate complex of INPP5B, but these attempts were not suc-
cessful. However, the very similar structures of the PtdIns(3,4)P2
and PtdIns(4)P complexes in INPP5B, together with the compre-
hensive interactions made in the active site including conserved
amino acids, suggest that the products can serve as goodmodel
for the binding of PtdIns substrates. The subsequent revelation
of a well-defined phosphate ion in the structure of OCRL in the
region where the 5-P moiety and the 5-phosphate product are
expected to bind allowed us to determine the position of the
scissile phosphate relative to the inositol ring in the substrate.
When overlaying PtdIns(4)P bound-INPP5B-cd and phosphate
bound-OCRL-cd, the distance between the departing 5-OH
and one of the oxygen atoms of the phosphate ion is only
0.6 A˚ (Figure 4A); therefore, we can consider that the free phos-
phate in OCRL-cd structure mimics the position of the 5-phos-
phate in the substrate.
The 5-P binds in a pocket containing six residues that are
highly conserved in the 5-phosphatases (Asn379, Lys380,
His400, Asp447, Asn449, and His549 in INPP5B; Figure 4A). At
this position, the 5-P interacts directly with Mg2+ and also makes
direct contacts with His400, His549, Asn449, and Asp 447.
Sequence similarities and mutagenesis studies support
that the 5-phosphatases are distant homologs of apurinic/apyr-
imidic (AP) endonucleases and might have a related mechanism
for phosphoryl transfer (Communi et al., 1996; Jefferson andreserved
Table 1. Data Collection and Refinement Statistics
Characteristics
INPP5B
SHIP-2 OCRLApo PtdIns-4-P1 bound PtdIns-3,4-P2 bound
Protein Data Bank number 3N9V 3MTC 4CML 3NR8 4CMN
Data collection
Synchrotron Diamond ESRF MaxLab BESSY Diamond
Beamline I03 ID29 I911-2 BL14.1 I03
Wavelength (A˚) 0.96860 0.97908 1.03796 0.91841 0.97920
Resolution range (A˚)a 72.55–2.65
(2.79–2.65)
94.51–2.40
(2.53–2.40)
29.89–2.30
(2.42–2.30)
44.77–2.80
(2.95–2.80)
103.78–3.13
(3.30–3.13)
Space group I212121 P213 P213 P1211 P4132
Unit-cell dimensions (A˚) a = 96.16 a = 133.76 a = 133.66 a = 44.80 a = 146.77
b = 110.66 b = 133.76 b = 133.66 b = 61.18 b = 146.77
c = 159.38 c = 133.76 c = 133.66 c = 114.32 c = 146.77
Unit-cell angles () – – – b = 91.9 –
Completeness (%)a 99.9 (99.9) 99.8 (99.9) 99.9 (100.0) 99.6 (99.5) 100.0 (100.0)
Unique reflections 25,062 31,417 35,595 15,338 10,068
Mean (I)/SD(I)a,b 11.9 (2.1) 11.1 (2.0) 12.5 (2.5) 7.9 (2.0) 55.6 (6.5)
Redundancya 4.6 (4.7) 4.8 (4.5) 5.5 (5.6) 4.6 (4.6) 40.5 (42.4)
Rmeas (%)
a,c 8.8 (69.8) 10.2 (79.1) 10.0 (71.2) 17.1 (81.2) 6.2 (80.1)
Refinement
Resolution range (A˚)a 53.66–2.65
(2.77–2.65)
47.29–2.40
(2.46–2.40)
28.5–2.30
(2.36–2.30)
20.0–2.80
(2.87–2.80)
48.92–3.13
(3.30–3.13)
Rcryst (%)
a,d 19.1 (26.3) 17.2 (27.0) 17.6 (32.9) 21.6 (32.1) 21.0 (24.5)
Rfree (%)
a,e 23.1 (33.1) 20.5 (36.9) 19.9 (37.3) 27.2 (40.2) 26.3 (35.1)
Model content
Protein atoms 4,645 2,538 2,510 4,791 2,690
Ligand atoms 0 43 47 0 17
Metal atoms 4 1 1 0 1
Water molecules 57 225 320 36 4
Wilson B factors (A˚2) 79.40 54.00 45.50 59.70 106.14
Average B factors (A˚2)
Protein atoms 74.10 54.08 34.34 41.49 114.53
Ligand atoms 72.46 54.92 – 114.22
Metal atoms 79.42 83.55 40.05 – 128.18
Water molecules 57.75 61.24 46.24 39.43 76.59
Rmsd bonds (A˚) 0.011 0.010 0.008 0.009 0.006
Rmsd angles () 1.255 1.278 1.243 1.142 0.997
Ramachandran plot (%)f (favored, outliers) 97.2, 0 97.1, 0.3 97.1, 0.7 93.58, 0 95.2, 0.3
aNumbers in parentheses represent outermost shell.
bMean (I)/SD(I) is the mean ratio for all reflections of < Ih > /sd < Ih > where, for each unique reflection h, < Ih > is the weightedmean of measured Ih and
sd < Ih > is the mean of estimated error sd(I).
cRmeas =
P
h

nh
nh1
P
l
jIhl  hIhij=P
h
P
l
hIhi
dRcryst =
PjFobs-Fcalcj=
P jFobsj;
where Fobs and Fcalc are respectively the observed and calculated structure factors.
eRfree is the same as Rcryst but based on a subset of 5% (4.58%, 4.9%, and 10% for Apo-INPP5B, SHIP-2, and OCRL, respectively) of reflections
omitted during refinement.
fValues computed by Molprobity (Chen et al., 2010).
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Substrate Processing by the PtdIns 5-phosphatasesMajerus, 1996; Whisstock et al., 2000). The detailed mechanism
of the hydrolysis reaction mediated by AP endonucleases is still
being debated and different models have been proposed. These
models include mechanisms involving either one or two Mg2+Structure 22ions, or alternatively one moving Mg2+ ion (Beernink et al.,
2001; Gorman et al., 1997; Mol et al., 2000).
In the ‘‘single-metal mechanism,’’ a hydroxide produced by
Asp210 (Asp447 in INPP5B) would perform a nucleophilic attack, 744–755, May 6, 2014 ª2014 Elsevier Ltd All rights reserved 747
Figure 2. Structural Determinants of the Specificity of the Different
5-Phosphatases
(A) Comparison in the P4IM motif between INPP5B-cd (green), SHIP2-cd
(magenta), OCRL-cd (copper), and SPsynaptojanin-cd (gray). diC8PtdIns(3,4)
P2 from INPP5B-cd complex structure is depicted as sticks with its phosphate
labeled in italic.
(B) Activity profiles of 5 human PtdIns 5- phosphatases monitoring hydrolysis
of diC8PtdIns(3,4,5)P3 and diC8PtdIns(4,5)P2. The concentration of substrate
was 50 mM and the concentration of enzyme was 3 nM (INPP5B, OCRL), 6 nM
(SYNJ1, SYNJ2), or 100 nM (SHIP2). The results are presented as means ± SD
of triplicate determinations.
See also the alignment of the ten human members of the 5-phosphatases
presented in Figure S1.
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Substrate Processing by the PtdIns 5-phosphataseson the phosphate and the transition state would be stabilized by
a metal coordinated by Asp70 (Asn275) and Glu96 (Glu403), His
309 (His549) being involved in the orientation and polarization of
the phosphate (Figures 4B and S3A; Mol et al., 2000). Then, a
complex between APE1 and twometals was produced following
crystallization under basic conditions. In this model, the hydrox-
ide performing the nucleophilic attack is coordinated by one
metal (labeled B in Figure 4C) that might also stabilize the transi-
tion state. The second metal (labeled A in Figure 4C) would also
either stabilize the transition state or the O30 departing group
(Beernink et al., 2001). Molecular dynamics studies have recently
proposed an alternative version of this model in which a single
metal would move from site B to site A during the catalytic cycle
and would help to generate the hydroxyl in the first part of the
reaction while retaining the product in the second part (Figures
4C and S3B; Oezguen et al., 2007).
Currently, there is still controversy about the biological exis-
tence of sites A and B. Lipton et al. (2008) conclude that only748 Structure 22, 744–755, May 6, 2014 ª2014 Elsevier Ltd All rightssite A exists when, on the other hand, complementary studies
by Oezguen et al. (2011) revealed that the presence of a metal
in site A only would destabilize the complex between APE1
and DNA.
Superimposition of the structures of the different 5-phospha-
tases with APE1, either complexedwith the products of the reac-
tion and one or two metals, revealed that the active sites of both
enzymes are highly conserved (Figures 4B and 4C). In Figure 4B,
it is noticeable that both the metals, the departing phosphate
groups (the free phosphate present in OCRL-cd structure being
used to identify the position of the scissile phosphate in the
5-phosphatase mechanism) and the sugar rings are shifted by
1.6–2.5 A˚ whereas the position of the residues involved in the
chemistry of the reaction are strictly conserved. It is likely that
the geometry of the reaction had to be slightly adjusted during
the course of the evolution to use a common structure to hydro-
lyze either a bulky nucleic acid or a relatively small membrane-
bound phospholipid. All residues surrounding the position of
the scissile phosphate (5-P) and Mg2+ ion in the 5-phosphatases
are strictly conserved in APE1, with only one exception: Asp70
(in APE1 structures) is replaced by either asparagines (in
INPP5B, OCRL, and SPsynaptojanin) or a glycine (SHIP2). The
high conservation supports similar reaction geometry during
the phosphoryl transfer reaction in the two enzyme families.
The Mg2+ ion present in INPP5B-cd and OCRL-cd structures
corresponds to the site A metal in APE1 (according to the
nomenclature proposed by Beernink et al., 2001). Similarly, in
all but one crystal structure of APE1, only site A was occupied
by a metal. In line with a recent proposal for APE1, a two-metal
or movingmetal mechanism is less likely to occur for the 5-phos-
phatases (Tsutakawa et al., 2013). Instead Mg2+ (in site A, as in
our structures) is proposed to play a major role to coordinate
the phosphate and stabilize highly negatively charged transition
state intermediates and the departing product phosphate, while
a water molecule is bound and activated in the pocket formed
by Asn449 and Asp447 in INPP5B. As in APE1, no residue in
the 5-phosphatase structures is located in a position suitable
to assist protonation of the departing 5-OH group. Instead, it
is likely that the neighboring Mg2+ bound water molecule, or a
phosphate group (4-P or 5-P) serves as the proton donors, or
assists in the proton transfer to the departing 5-OH.
Structure of SHIP2—A Target for Obesity and Type 2
Diabetes
SHIP2 has recently attracted significant attention due to its role
in negative regulation of insulin signaling and as a potential
drug target for obesity and type 2 diabetes (Sasaoka et al.,
2006; Suwa et al., 2010a). SHIP2 has a preference for
Ins(1,3,4,5)P4, PtdIns(3,5)P2 and PtdIns(3,4,5)P3 but is unable
to mediated hydrolysis of PtdIns(4,5)P2 as shown in Chi et al.
(2004), Pesesse et al. (1998), and in Figure 3B. Therefore, it
appears to have a stronger requirement for the presence of
the 3-P phosphate in the substrate than other members of the
5-phosphatase family. This is consistent with its proposed role
as a negative regulator of PtdIns(3,4,5)P3 levels at the plasma
membrane, thereby attenuating the Akt pathway-mediated
insulin signaling.
SHIP2 is a modular protein composed in addition to its cata-
lytic domain of an N-terminal SH2, C-terminal proline-rich, andreserved
Figure 3. Binding Mode of the Product Analogs to INPP5B-cd
(A and B) Interactions between INPP5B-cd and either diC8PtdIns(3,4)P2 (A) or diC8PtdIns(3)P1 (B): interactions with head group phosphates. Polar and van der
Waals interactions between INPP5B-cd and product analogs are shown as yellow and green dashes, respectively. Residues belonging to the P4IM motif are
circled in purple.
(C) INPP5B-cd/diC8PtdIns(3,4)P2 binding-mode: interactions with phosphate P1. DiC8PtdIns(3,4)P2 is displayed as sticks with the corresponding 2mFo-DFc
electron density contoured at 1 s. LC1R and LC2R motifs are orange and green, respectively. Interactions between phosphate P1 and INPP5B-cd residues are
depicted by green dashes.
(D) Ligplot diagram of interactions between INPP5B-cd and diC8PtdIns(3,4)P2. Protein and ligand covalent bonds are orange and purple, respectively. Water
molecules are shown as cyan spheres. H-bonds and salt-bridges are represented by green dashes and hydrophobic interactions by red lines. Distances between
two interacting atoms are written in green (in angstroms).
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Substrate Processing by the PtdIns 5-phosphatasesSAM domains. These three particular domains are involved
in protein-protein interactions, notably playing a role in mem-
brane-targeting of the enzyme. We have restricted our study to
the catalytic domain of SHIP2 (referred as SHIP2-cd).
The structure of apo SHIP2-cd, determined at 2.80 A˚ resolu-
tion, shows a similar overall fold as INPP5B-cd and OCRL
(rmsd is 1.2 A˚ for 265 and 266 superimposed residues, 30.7%
and 29.3% sequence identity, respectively) but major local dif-
ferences in the regions involved in substrate-binding (Figures
1B and 2A). Modeling of the PtdIns(3,4)P3 product into SHIP2
based on the INPP5B complex confirms that most residues in-
teracting with 1-P and 5-P units of the substrate are conserved
and are positioned similarly (Figure 4A), suggesting that the gen-
eral substrate binding mode will be similar. Major differences in
the SHIP2 structure, likely to be key for its specific biological
function, are found in the P4IM motif. The loop including P4IM
is 7 residues longer in SHIP2 than in INPP5B (Figure 2A). This
loop is disordered in one of two molecules present in the
asymmetric unit. The additional extension in SHIP2 makes this
loop quite different than the corresponding loop in INPP5B. In
SHIP2, Arg682 and Asn684 are well positioned to interact with
both 3-P and 4-P of the substrate.Structure 22A recent study based upon analysis of a complex between
SHIP2 and a specific competitive inhibitor revealed that, upon
binding, the P4IM motif fold over the inhibitor (Mills et al., 2012).
Therefore, this loop could similarly fold over the 3-P and 4-P
positions of the substrate, thereby allowing more extensive sub-
strate interactions. The interaction between Arg682 and 3-P is
likely the driving force of this conformational change, thereby ex-
plaining the restricted specificity of SHIP2 (and closest homolog
SHIP1) toward substrates harboring phosphates in position 3.
Implications for Substrate Binding in other Human 5-
Phosphatases
Our structural analysis, taken together with the conservation of
key residues and functionalities, has broader implications for
the human 5-phosphatase family. The structural and sequence
data suggest that the 5-phosphatases recognize their substrates
in a very similar manner, involving several conserved residues
interactingwith the 1-P, 4-P and5-Pmoieties. Lys380, interacting
with1-P, is conserved in all human5-phosphatases, togetherwith
the neighboring Gly381 (See Figure S1 for sequence alignment).
The other key residue in 1-P interaction, Asn379, is conserved
in all human 5-phosphatases except INPP5E and INPP5A, where, 744–755, May 6, 2014 ª2014 Elsevier Ltd All rights reserved 749
Figure 4. 5-Phosphatases Catalytic Mechanism: Comparison with Representative Human Apurinic/Apyrimidinic Endonuclease, Ape1
(A) Superimposition of INPP5B-cd (green), SHIP2-cd (magenta), OCRL-cd (copper), and SPsynaptojanin-cd (gray) in the active site. The free phosphate present in
OCRL-cd structure is depicted as sticks and labeled as ‘‘P5.’’ Mg2+ ions present in INPP5B-cd/diC8PtdIns(3,4)P2 complex andOCRL-cd are displayed as orange
and sand spheres, respectively. Polar interactions between P1, the putative P5 site, and INPP5B-cd residues are shown as dashes.
(B) Superimposition of INPP5B-cd (green), SHIP2-cd (magenta), OCRL-cd (copper), SPsynaptojanin-cd (gray), and Ape1 (salmon) complexed to the two products
of its reaction. In addition to the features reproduced from (A), the two nucleic acids present in the Ape1 structure are displayed as thin sticks with their carbon
atoms colored white. Mg2+ ion (INPP5B-cd structure) and Mn2+ (Ape1 structure) are shown as orange and green spheres, respectively.
(C) Superimposition of INPP5B-cd (green), SHIP2-cd (magenta), OCRL-cd (copper), SPsynaptojanin-cd (gray), and Ape1 (salmon) complexed to Pb2+ ions. The
two Pb2+ ions present in the Ape1 structure are dark gray.
See also the two possible catalytic mechanisms presented in Figure S3.
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Substrate Processing by the PtdIns 5-phosphatasesit is replaced by Thr and Arg, respectively. INPP5A only transform
soluble InsP substrates, and an additional positive charge at this
position might provide additional 1-P interactions. Ala403, which
recognizes the inositol ring, is conserved as a small side chain in
most human family members (as alanine or serine) indicating
similar interactions with substrate inositol groups.
Most of the human 5-phosphatases prefer substrates phos-
phorylated at the 4-position. Lys516 interacting with the 4-P po-
sitions is conserved in all 5-phosphatase family members except
INPP5A (Asp), but is positioned differently in SHIP2, as revealed
by our structure (Figure 2A). Arg518, also interacting with the 4-P
position, is conserved in all family members except SHIP1 and
SHIP2, which, as discussed above, have an insertion in this
region. Together, this also suggests that the 4-P recognition is
similar in most of the family members.
Membrane Interaction by Human 5-Phosphatase
Catalytic Domains
Although the membrane localization of the human 5-phospha-
tases is often assisted by interactions through accessory do-
mains either directly to the membrane or to other membrane
localized proteins (Astle et al., 2006), the purified catalytic
domains of most human 5-phosphatases are active toward
liposome-containing phosphoinositide substrates. Therefore, a
specific surface of the catalytic domain has evolved to mediate
these interactions. The INPP5B structure reveals an extensive
hydrophobic surface in the enzyme-lipophilic substrate com-
plexes (Figure 3C). This region contains residues belonging
to LC1R and LC2R motifs (Phe312, Phe313, Met374, and
Met377) that interact with the aliphatic region of the diC8PtdInsP
substrates, as discussed above. In the crystal lattice, the
aliphatic chains of diC8PtdInsPs from three different crystallo-
graphic relatedmolecules interact with some of these hydropho-
bic residues forming a highly hydrophobic cluster (Figure 5G).
Several additional potential interaction points with head groups
of phospholipids, or other negatively charged lipids, are lining
this potential membrane interacting region (His314, Lys308,750 Structure 22, 744–755, May 6, 2014 ª2014 Elsevier Ltd All rightsArg376, and Arg410). Furthermore, a sulfate ion bound to
Lys308 and the backbone amide of Ser307 could mark an inter-
action with a phospholipid head group (Figure 5A). Together,
these findings suggest that this constitutes a likely membrane-
interacting region. This relatively extensive interaction surface
suggests that the protein will penetrate into the lipid bilayer to ac-
cess the substrate. The hydrophobic patch and the sequence
motif defining the binding of the aliphatic moiety of the sub-
strates to INPP5B are also present in OCRL, supporting a similar
membrane interaction for OCRL.
The putative position of the membrane upon interaction with
the 5-phosphatases for INPP5B-cd, SHIP2-cd, and OCRL-cd
was calculated using the positioning of protein in membrane
(PPM) server. The algorithm proposes the zone of interaction
between a protein and a membrane by finding the region whose
transfer energy between water and a lipid layer is minimal
(Lomize et al., 2006, 2012). The predictions, in all cases, agree
well with our hypothesis based upon visual observations of the
models (Figures 5D–5F) and define the LCRs motifs as mem-
brane-interacting regions.
As discussed above, the high degree of conservation of
residues involved in 1-P, 4-P, and 5-P interactions suggest
that phosphoinositides interact in the same way in most of the
5-phosphatases. For geometric reasons, it is therefore likely
that similar regions of the proteins are involved in membrane in-
teractions, albeit detailed interactions can be made quite differ-
ently. The LC1R and LC2R regions contain hydrophobic residues
in most of the family members. However, SHIP1 and SHIP2 lack
the region corresponding to the LC1R-motif in INPP5B, and the
structure of SHIP2 confirms that no other residues are substitut-
ing for the LC1R-motif in this region. Because our activity data
indicate a very low activity of the isolated SHIP2 catalytic domain
on the diC8PtdInsP substrates, it might be that its activity ismore
dependent on the membrane binding and interactions mediated
by other domains. For instance, the N-terminal SH2 domain in
SHIP2 contributes tomembrane localization indirectly by binding
to the adaptor proteins Shc and p130CAS or directly by bindingreserved
Figure 5. Structural Model of Association of 5-Phosphatases to the Membrane
(A–C) Electrostatic potential surface of INPP5B-cd bound to diC8PtdIns(3,4)P2 (A), apo-SHIP2 (B), and apo-OCRL (C). The loop encompassing residues 533–538 in
SHIP2wasmodeled after the corresponding loop in INPP5B-cd.Mg2+ ion from INPP5B-cdwas also docked in themodel used to compute electrostatic potentials.
Themoleculeof diC8PtdIns(3,4)P2 is shownasaball andsticksmodel, thesulfate ionasavanderWaals sphere, and theputative interactionplanwith themembrane
as a green line. In (B) and (C), the molecule of diC8PtdIns(3,4)P2 is issued from a superimposition between INPP5B-cd and either SHIP2-cd (B) or OCRL-cd (C).
(D–F) Location of the membrane plan determined by the PPM server for INPP5B-cd bound to diC8PtdIns(3,4)P2 (D), SHIP2-cd (E), and OCRL-cd (F). The
membrane plan is represented by transparent green spheres.
(G) The 3-fold crystallographic axis constituted by the assembly of LC1R and LC2Rmotifs. Themolecular surface of residues belonging to LC1R and LC2Rmotifs
is yellow.
(H) Suggested membrane-interacting regions in INPP5B-cd (cyan) bound to diC8PtdIns(3,4)P2 and SPsynaptojanin-cd (gray) bound to Ins(1,4)P2. Ligands are
displayed as sticks with their carbon atoms colored either yellow (diC8PtdIns(3,4)P2) or pink (Ins(1,4)P2). Residues interacting with the membrane are shown as
molecular surface.
(I) Comparison between INPP5B-cd (green) and SPsynaptojanin-cd (gray) complexes with diC8PtdIns(3,4)P2 (yellow) and Ins(1,4)P2 (pink), respectively. This
represents a close-up view of the boxed region on Figure 5G. Phosphate positions are labeled in green (INPP5B-cd complex) and gray (SPsynaptojanin complex).
Mg2+ ion in INPP5B-cd is shown as an orange sphere, Ca2+ ion in SPsynaptojanin-cd as a green sphere.
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Substrate Processing by the PtdIns 5-phosphatasesto hepatocyte growth factor receptor c-Met (Koch et al., 2005;
Prasad et al., 2001; Wisniewski et al., 1999).DISCUSSION
Understanding the molecular details of enzymes in the PtdInsP
pathways has been challenging, partly due to difficulties in struc-
tural and biochemical work on lipid- and membrane-interacting
proteins. Using efficient screening techniques, we identified
constructs of three human 5-phosphatases allowing high-reso-
lution structural studies, as well as stabile complexes with
lipid-like products for one of these enzymes to be generated.
Conserved sequence motifs support a conserved interaction
mode with the PtdInsP head group in most human 5-phospha-
tases, as seen in INPP5B. Consequently, similar regions of these
proteins are likely to be involved in membrane interactions, and
the nature of the substrate interactions in INPP5B is consistent
with a model where the catalytic domain inserts slightly into
the membrane to access substrates.
We note that the Ins(1,4)P2 product binding mode in the
SPsynaptojanin structure is very different from that of our lipid-
like PtdInsP products in INPP5B (Tsujishita et al., 2001; Figures
1C and 5I). Ins(1,4)P2 was also used as a model for interactions
of SPsynaptojanin with PtdInsP, leading to the proposal of a very
different membrane interacting surface to the one we observe in
INPP5B (Figure 5H). The interactions of the P1 of Ins(1,4)P2
SPsynaptojanin do not involve any conserved residues and
only one hydrogen bond is made, with the main chain amide of
Tyr704. Because residues for PtdInsP head group interactions
in INPP5B are conserved in SPsynaptojanin including P1 inter-
actions, we feel that substrate and membrane interactions in
SPsynaptojanin need to be reevaluated.
This is of a special importance to increase the chances of suc-
cess of the various drug development initiatives that target the
5-phosphatase family members. For instance, small-molecule
inhibitors of SHIP2 were recently shown to lower plasma glucose
levels and improve glucose intolerance in diabetic mice (Annis
et al., 2009; Ichihara et al., 2013; Suwa et al., 2009, 2010b). Addi-
tionally, evidence that SHIP2 and its close homolog SHIP1 act as
proto-oncogenes is emerging and specific inhibitors toward this
enzymes show promising effects on breast cancer and multiple
myeloma models (Fuhler et al., 2012). In vitro and in vivo (on ro-
dent models) studies have revealed the potential of AQX-1125,
an activator of SHIP1, in anti-inflammatory therapy. This mole-
cule is now in phase II clinical trials (Stenton et al., 2013a, 2013b).
In conclusion, we presented an updated model describing
interactions between the 5-phosphatases and their ligands.
This allowed us to identify important residues for ligand binding,
catalysis, and membrane interaction. Due to the importance of
the 5-phosphatases in human health, the structural and mecha-
nistic models can support the design of specific inhibitors for a
particular 5-phosphatase.EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The sequences encoding INPP5B-cd residues 262–566 (apo structure) or
residues 259–563 (products complexes structures) and OCRL-cd residues
215–560 were subcloned into the vector pNIC-CH2 adding a C-terminal752 Structure 22, 744–755, May 6, 2014 ª2014 Elsevier Ltd All rights6 3 His-tag. The sequences encoding SYNJ1-cd residues 508–901 and
SYNJ2-cd residues 506–984 were subcloned into the vector pNIC-Bsa4.
The sequence encoding SHIP2-cd residues 419–832 was subcloned into the
vector pNIC-MBP. In the pNIC-Bsa4 vector and pNIC-MBP vectors, an N-ter-
minal 6 3 His-tag is added to the proteins. The proteins were expressed in
Escherichia coli and purified from the soluble fraction of the cell lysate bymetal
affinity chromatography followed by gel filtration. The His-tag was removed
from SHIP2 by incubating with TEV protease. To remove any bound metals
from the proteins, EDTA was added to the purified proteins and subsequently
removed by dialysis. Detailed protocol including buffer composition is pre-
sented in the Supplemental Experimental Procedures.
Crystallization
All crystallization experiments were performed using the sitting-drop method.
Protein concentrations used in the crystallization screens were 31.5, 21.7, 18,
14.7, and 17.1 mg/ml for apo-INPP5B-cd, PtdIns(4)P1-bound INPP5B-cd,
PtdIns(3,4)P2-bound INPP5B-cd, SHIP2-cd, andOCRL-cd, respectively. Prior
to setting up the crystallization trials, proteins were incubated on ice with
either 2 mM biphenyl 2,30,4,50,6-pentakisphosphate (apo-INPP5B-cd), or
2 mM MgCl2 and 1mM diC8PtdIns(4)P (PtdIns(4)P1-bound INPP5B-cd),
or 2 mM MgSO4 and diC8PtdIns(3,4)P2 (PtdIns(3,4)P2-bound INPP5B-cd),
or 2 mM biphenyl 2,30,4,50,6-pentakisphosphate and 2 mM MgSO4 (SHIP2-
cd). For SHIP2-cd, the same crystal form could also be obtained without
added biphenyl 2,30,4,50,6-pentakisphosphate. Structure determination at
3.2 A˚ of these crystals showed identical structure to the one with biphenyl
2,30,4,50,6-pentakisphosphate within experimental errors. Thus, the presence
of this ligand might not have influenced the conformation of the protein espe-
cially because no residual density corresponding to it could be observed in the
resulting electron density maps. Crystals were obtained by mixing 0.1 ml of
precipitant with either 0.1 ml of protein solution (apo-INPP5B-cd, PtdIns(4)
P1-bound INPP5B-cd and OCRL-cd) or 0.3 ml of protein solution (PtdIns(3,4)
P2-bound INPP5B-cd and SHIP2-cd.) For apo-INPP5B-cd, PtdIns(4)P1- and
PtdIns(3,4)P2-bound INPP5B-cd, SHIP2-cd, and OCRL-cd precipitant solu-
tions corresponded respectively to conditions D6, G2, F10, B9, and E7 from
the JCSG+ Suite (QIAGEN; detailed composition of these conditions can be
found in the Supplemental Experimental Procedures section). Crystals were
then transferred into a cryosolution identical to the reservoir except that
both the additives used before the crystallizations experiments and 25% glyc-
erol (ethylene-glycol for SHIP2-cd crystals) were added, and that the concen-
tration of the precipitating agent was increased by 10%. Freezing and storage
of the crystals were performed in liquid nitrogen. Experimental procedures
related to X-ray data collection, processing, structure determination; and
refinement are provided in the Supplemental Experimental Procedures.
Malachite Green Phosphatase Activity Assay
The enzyme activity of the metal-chelated recombinant catalytic domains of
PtdIns 5-phosphatases was measured using a malachite green phosphate
assay kit (BioAssay Systems). Phosphatases were incubated with 50 mM
diC8PtdIns(3,4,5)P3 or diC8PtdIns(4,5)P2 at 30C for 5 min in a buffer contain-
ing 20mMHEPES, 300mMNaCl, 20%glycerol, 2mMTCEP, and 2mMMgCl2,
at pH 7.5 in a volume of 25 ml. The concentration enzyme varied between
different PtdIns 5-phosphatases (3–100 nM). Six microliters 10% (w/v) tri-
chloroacetic acid was added to quench the reaction. Subsequently, 69 ml
H2O was added followed by 25 ml malachite green reagent. The mixture was
allowed to develop for 30min and the optical density at 620 nmwasmeasured.
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